Template:Symptomatic bradycardia: Difference between revisions
| Line 17: | Line 17: | ||
**[[Beta-blocker toxicity|B-blocker]] | **[[Beta-blocker toxicity|B-blocker]] | ||
**[[Calcium channel blocker toxicity|Ca-channel blocker]] | **[[Calcium channel blocker toxicity|Ca-channel blocker]] | ||
**[[Clonidine toxicity|Clonidine]] | |||
**[[Digoxin toxicity]] | **[[Digoxin toxicity]] | ||
**[[Ethanol]] | |||
**[[Opioids]] | **[[Opioids]] | ||
**[[Organophosphate toxicity|Organophosphates]] | **[[Organophosphate toxicity|Organophosphates]] | ||
**[[ | **[[Xylazine toxicity]] | ||
*'''Infectious/Postinfectious''' | *'''Infectious/Postinfectious''' | ||
**[[Chagas disease]] | **[[Chagas disease]] | ||
Latest revision as of 15:43, 15 March 2023
Symptomatic bradycardia
- Cardiac
- Inferior MI (involving RCA)
- Sick sinus syndrome
- Neurocardiogenic/reflex-mediated
- Increased ICP
- Vasovagal reflex
- Hypersensitive carotid sinus syndrome
- Intra-abdominal hemorrhage (i.e. ruptured ectopic)
- Metabolic/endocrine/environmental
- Hyperkalemia
- Hypothermia (Osborn waves on ECG)
- Hypothyroidism
- Hypoglycemia (neonates)
- Toxicologic
- Infectious/Postinfectious
- Other